Media stories about TRACON Pharmaceuticals (NASDAQ:TCON) have trended somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. TRACON Pharmaceuticals earned a media sentiment score of 0.25 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.3271426177876 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Separately, Zacks Investment Research lowered shares of TRACON Pharmaceuticals from a “buy” rating to a “hold” rating and set a $4.00 price objective on the stock. in a report on Friday, January 5th.
Shares of TRACON Pharmaceuticals (NASDAQ TCON) traded up $0.10 during mid-day trading on Friday, hitting $2.65. 138,480 shares of the stock traded hands, compared to its average volume of 196,897. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.06 and a current ratio of 3.06. TRACON Pharmaceuticals has a 52-week low of $2.00 and a 52-week high of $4.60. The firm has a market cap of $45.26, a price-to-earnings ratio of -2.32 and a beta of 2.23.
WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect TRACON Pharmaceuticals (TCON) Share Price” was originally published by BBNS and is the property of of BBNS. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://baseballnewssource.com/2018/03/17/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-tracon-pharmaceuticals-tcon-share-price/2002429.html.
About TRACON Pharmaceuticals
TRACON Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.